Table 2.
First author, year | Country | Reporting quality of the paper | Study period | Representative of whole country? | Enzyme or mutational diagnosis? | Prenatal diagnosis included? | Evidence of ethnicity founder effect? | Sanfilippo all subtypes (sum of specific types) | ||
---|---|---|---|---|---|---|---|---|---|---|
Number of patients | Patients per 100,000 live births | Estimation method | ||||||||
Al-Maawali, 2012 [15] | Oman | Poor | 1998–2007 | No | Yes | No | No | All MPS III: 7 | 1.72 | Dx |
Angelis, 2015 [16] | Europe | Review | No data | Not applicable | Not applicable | – | – | – | 1.42 (range, 0.36–2.00) | Dx |
Baehner, 2005 [17] | Germany | Good | 1980–1995 | Yes | Yes | No | Yes (Turkish) | All MPS III: 211 | 1.57 | Dx |
Ben Turkia, 2009 [14] | Tunisia | Poor | 1988–2005 | Yes | Yes | No | No | All MPS III: 24 | 0.70 | Dx |
Gómez, 2012 [18] | Colombia | – | 1998–2007 | No | No data | No data | No data | – | 0.17 | Dx |
Héron, 2011 [19] | France | Medium | 1990–2006 | Yes | Yes | No | No | All MPS III: 128 | 0.82a | Dx |
Héron, 2011 [19] | Greece | Medium | 1990–2006 | Yes | Yes | No | No | All MPS III: 20 (including 1 unclassified) | 0.97 | Dx |
Héron, 2011 [19] | Great Britain | Medium | 1990–2006 | Yes | Yes | No | No | All MPS III: 126 (including 6 unclassified) | 1.21 | Dx |
Hult, 2014 [20] | Sweden | Medium | 1990–2009 | Yes | Yes | No | No | All MPS III: 21 | 1.01 | Dx |
Joshi, 2002 [21] | Oman | Poor | 1998–2000 | No | Yes | No | No | All MPS III: 3 | 2.35 | Dx |
Jurecka, 2015 [22] | Poland | Good | 1970–2010 | Yes | Yes | No data | No | All MPS III: 186 | 0.86 | Dx |
Lin, 2009 [23] | Taiwan | Good | 1984–2004 | Yes | Yes | No | No | All MPS III: 25 | 0.39 | Dx |
Malm, 2008 [12] | Norway | Medium | 1979–2007 | Yes | Yes | No data | No | All MPS III: 4 | 0.27 | Real lifetime riskb |
Malm, 2008 [12] | Denmark | Medium | 1975–2007 | Yes | Yes | No data | No | All MPS III: 8 | 0.43 | Real lifetime riskb |
Malm, 2008 [12] | Sweden | Medium | 1975–2007 | Yes | Yes | No data | No | All MPS III: 20 | 0.67 | Real lifetime riskb |
Moammar, 2010 [24] | Saudi Arabia | Poor | 1983–2008 | Yes | Yes | No | No | All MPS III: 3 | 2.00 | Dx |
Nelson, 1997 [25] | Great Britain | Poor | 1958–1985 | No | Yes | No | No | All MPS III: 3 | 0.36 | Dx |
Nelson, 2003 [26] | Australia | Poor | 1969–1996 | Yes | Yes | Yes | No | All MPS III: 11 | 1.71 | Dx |
Pinto, 2004 [27] | Portugal | Poor | 1982–2001 | No (Northern Portugal) | Yes | Yes | No | All MPS III: 14 | 0.84c | DoB |
Poorthuis, 1999 [28] | The Netherlands | Poor | 1970–1996 | Yes | Yes | Yes | No | All MPS III: 156 (diagnosed between 1970 and 1996) | 1.89c | DoB |
Poupetová, 2010 [13] | Czech Republic | Medium | 1975–2008 | Yes | Yes | Yes | No | All MPS III: 24 (diagnosed between 1975 and 2008) | 0.91c | DoB |
aThe original paper reported 0.73, which is possibly a misprint, as the sum of subtypes is 0.82
bDiagnosed patients among defined cohorts
cMPS III all subtypes but refers to the subtypes on different time horizons
DoB date-of-birth method, Dx diagnosis period method, MPS mucopolysaccharidosis